Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-08-2012 | Review

Challenging the effectiveness of green tea in primary and tertiary cancer prevention

Authors: Hirota Fujiki, Kazue Imai, Kei Nakachi, Masahito Shimizu, Hisataka Moriwaki, Masami Suganuma

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2012

Abstract

Purpose

Drinking green tea daily is part of Japanese culture, and various studies have revealed that green tea is a cancer preventive. We here review our progress in cancer prevention with green tea on 12 main topics, from basic to clinical level.

Topics and methods

Biochemical and biological studies of green tea catechins, a prospective cohort study, preclinical safety trials with tablets of green tea extract, double-blind randomized clinical phase II prevention trial for recurrence of colorectal adenomas, and synergistically enhanced inhibition by the combination of green tea catechins and anticancer drugs. All results were significant, including human studies with informed consent.

Results

Drinking 10 Japanese-size cups of green tea per day delayed the cancer onset of humans 7 years for females. For tertiary cancer prevention, consuming 10 cups of green tea per day fortified by green tea tablets, 50 %, significantly prevented the recurrence of colorectal adenomas. A minimum effective amount of green tea catechins for cancer prevention was found in humans. In addition, the combination of green tea catechins and anticancer drugs engendered a new cancer therapeutic strategy.

Conclusion

The consumption of 10 Japanese-size cups of green tea per day is a significant factor in primary cancer prevention for the general population, and the preventive effect on recurrence of colorectal adenomas in patients is vital evidence in tertiary cancer prevention.

Adachi S, Nagao T, Ingolfsson HI, Maxfield FR, Andersen OS, Kopelovich L, Weinstein IB (2007) The inhibitory effect of (−)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res 67:6493–6501PubMedCrossRef

Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H (1997) Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 89:1881–1886PubMedCrossRef

Ben-Neriah Y, Karin M (2011) Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 12:715–723PubMedCrossRef

Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A (2006) Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66:1234–1240PubMedCrossRef

Chen W, Dong Z, Valcic S, Timmermann BN, Bowden GT (1999) Inhibition of ultraviolet B-induced c-fos gene expression and p38 mitogen-activated protein kinase activation by (−)-epigallocatechin gallate in a human keratinocyte cell line. Mol Carcinog 24:79–84PubMedCrossRef

Conney AH, Wang ZY, Huang MT, Ho CT, Yang CS (1992) Inhibitory effect of oral administration of green tea on tumorigenesis by ultraviolet light, 12-O-tetra decanoylphorbol-13-acetate and N-nitrosodiethylamine in mice. CRC Press, Boca Raton, pp 361–373

El-Deiry WS, Harper JW, O’Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B (1994) WAF1/CIP1 is induced in p53-mediated G₁ arrest and apoptosis. Cancer Res 54:1169–1174PubMed

Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N, other National Surgical Adjivant Breast and Bowel Project Inverstigators (1998) Tamoxifen for prevention of breast cancer. Report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90:1371–1388PubMedCrossRef

Fujiki H (1999) Two stages of cancer prevention with green tea. J Cancer Res Clin Oncol 125:589–597PubMedCrossRef

Fujiki H (2005) Green tea: health benefits as cancer preventive for humans. Chem Rec 5:119–132PubMedCrossRef

Fujiki H, Okuda T (1992) (−)-Epigallocatechin gallate. Drugs Future 17:462–464

Fujiki H, Suganuma M (2002) Green tea and cancer prevention. Proc Jpn Acad 78(B):263–270CrossRef

Fujiki H, Suganuma M (2011) Tumor promoters-microcystin-LR, nodularin and TNF-α and human cancer development. Anticancer Agents Med Chem 11:4–18PubMedCrossRef

Fujiki H, Suganuma M, Okabe S, Komori A, Sueoka E, Sueoka N, Kozu T, Sakai Y (1996) Japanese green tea as a cancer preventive in humans. Nutr Rev 54:S67–S70PubMedCrossRef

Fujiki H, Suganuma M, Okabe S, Sueoka E, Sueoka N, Fujimoto N, Goto Y, Matsuyama S, Imai K, Nakachi K (2001) Cancer prevention with green tea and monitoring by a new biomarker, hnRNP B1. Mutat Res 480–481:299–304PubMed

Fujiki H, Suganuma M, Imai K, Nakachi K (2002) Green tea: cancer preventive beverage and/or drug. Cancer Lett 188:9–13PubMedCrossRef

Fujiki H, Takeuchi H, Nishitani N, Yamanaka H, Suzuki K, Kurusu M, Suganuma M (2004) Carcinogenic potential of tobacco tar-resistant Staphylococcus aureus in buccal cavity. J Cancer Res Clin Oncol 130:301–305PubMedCrossRef

Fujita Y, Yamane T, Tanaka M, Kuwata K, Okuzumi J, Takahashi T, Fujiki H, Okuda T (1989) Inhibitory effect of (−)-epigallocatechin gallate on carcinogenesis with N-ethyl-N’-nitro-N-nitrosoguanidine in mouse duodenum. Jpn J Cancer Res 80:503–505PubMedCrossRef

Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H (2001) Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 98:10350–10355PubMedCrossRef

Hecker E, Adolf W, Hergenhahn R, Schmidt R, Sorg B (1984) Irritant diterpene ester promoters of mouse skin: contributions to etiologies of environmental cancer and to biochemical mechanisms of carcinogenesis. In: Fujiki H, Hecker E, Moore RE, Sugimura T, Weinstein IB (eds) Cellular interactions by environmental tumor promoters. Jpn Sci Soc Press/VNU Science Press, BV, Tokyo/Utrecht, pp 3–36

Imai K, Suga K, Nakachi K (1997) Cancer-preventive effects of drinking green tea among a Japanese population. Prev Med 26:769–775PubMedCrossRef

Iwasaki M, Inoue M, Sasazuki S, Sawada N, Yamaji T, Shimazu T, Willett WC, Tsugane S (2010) Green tea drinking and subsequent risk of breast cancer in a population to based cohort of Japanese women. Breast Cancer Res 12:R88. (Epub ahead of print)

Komori A, Yatsunami J, Okabe S, Abe S, Hara K, Suganuma M, Kim SJ, Fujiki H (1993a) Anticarcinogenic activity of green tea polyphenols. Jpn J Clin Oncol 23:186–190PubMed

Komori A, Yatsunami J, Suganuma M, Okabe S, Abe S, Sakai A, Sasaki K, Fujiki H (1993b) Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. Cancer Res 53:1982–1985PubMed

Kuzuhara T, Sei Y, Yamaguchi K, Suganuma M, Fujiki H (2006) DNA and RNA as new binding targets of green tea catechins. J Biol Chem 281:17446–17456PubMedCrossRef

Kuzuhara T, Tanabe A, Sei Y, Yamaguchi K, Suganuma M, Fujiki H (2007a) Synergistic effects of multiple treatments, and both DNA and RNA direct bindings on, green tea catechins. Mol Carcinog 46:640–645PubMedCrossRef

Kuzuhara T, Suganuma M, Kurusu M, Fujiki H (2007b) Helicobacter pylori-secreting protein Tipα is a potent inducer of chemokine gene expressions in stomach cancer cells. J Cancer Res Clin Oncol 133:287–296PubMedCrossRef

Kuzuhara T, Suganuma M, Fujiki H (2008) Green tea catechin as a chemical chaperone in cancer prevention. Cancer Lett 261:12–20PubMedCrossRef

Laurie SA, Miller VA, Grant SC, Kris MG, Ng KK (2005) Phase 1 study of green tea extract in patients with advanced lung cancer. Cancer Chemother Pharmacol 55:33–38PubMedCrossRef

Nakachi K, Suemasu K, Suga K, Takeo T, Imai K, Higashi Y (1998) Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn J Cancer Res 89:254–261PubMedCrossRef

Nakachi K, Matsuyama S, Miyake S, Suganuma M, Imai K (2000) Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. BioFactors 13:49–54PubMedCrossRef

Narisawa T, Fukaura Y (1993) A very low dose of green tea polyphenols in drinking water prevents N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 84:1007–1009PubMedCrossRef

NCI, Dcpc, Chemoprevention Branch and Agent Development Committee (1996) Clinical development plan:tea extracts green tea polyphenols epigallocatechin gallate. J Cell Biochem 26S:236–257

Nishida H, Omori M, Fukutomi Y, Ninomiya M, Nishiwaki S, Suganuma M, Moriwaki H, Muto Y (1994) Inhibitory effects of (−)-epigallocatechin gallate on spontaneous hepatoma in C3H/HeNCrj mice and human hepatoma-derived PCL/PRF/5 cells. Jpn J Cancer Res 85:221–225PubMedCrossRef

Novoa I, Zeng H, Harding HP, Ron D (2001) Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2α. J Cell Biol 153:1011–1022PubMedCrossRef

Ogunleye AA, Xue F, Michels KB (2010) Green tea consumption and breast cancer risk or recurrence: a meta-analysis. Breast Cancer Res Treat 119:477–484PubMedCrossRef

Okabe S, Suganuma M, Hayashi M, Sueoka E, Komori A, Fujiki H (1997) Mechanisms of growth inhibition of human lung cancer cell line, PC-9, by tea polyphenols. Jpn J Cancer Res 88:639–643PubMedCrossRef

Okabe S, Ochiai Y, Aida M, Park K, Kim SJ, Nomura T, Suganuma M, Fujiki H (1999) Mechanistic aspects of green tea as a cancer preventive: effect of components on human stomach cancer cell lines. Jpn J Cancer Res 90:733–739PubMedCrossRef

Okabe S, Fujimoto N, Sueoka N, Suganuma M, Fujiki H (2001) Modulation of gene expression by (−)-epigallocatechin gallate in PC-9 cells using a cDNA expression array. Biol Pharm Bull (Tokyo) 24:883–886CrossRef

Okuda T, Mori K, Hayatsu H (1984) Inhibitory effect of tannins on direct-acting mutagens. Chem Pharm Bull (Tokyo) 32:3755–3758CrossRef

Okuda T, Mori K, Hatano T (1985) Relationship of the structure of tannins to the binding activities with hemoglobin and methylene blue. Chem Pharm Bull (Tokyo) 33:1424–1433CrossRef

Pisters KM, Newman RA, Coldman B, Shin DM, Khuri FR, Hong WK, Glisson BS, Lee JS (2001) Phase 1 trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 19:1830–1838PubMed

Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, Araki H, Suganuma M, Fujiki H, Moriwaki H (2008) Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev 17:3020–3025PubMedCrossRef

Shimizu M, Adachi S, Masuda M, Kozawa O, Moriwaki H (2011) Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. Mol Nutr Food Res 55:832–843PubMedCrossRef

Sporn MB, Dunlop NM, Newton DL, Smith JM (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332–1338PubMed

Stingl JC, Ettrich T, Muche R, Wiedom M, Brockmöller J, Seeringer A, Seufferlein T (2011) Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomized controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population. BMC Cancer 11:360PubMedCrossRef

Sueoka N, Suganuma M, Sueoka E, Okabe S, Matsuyama S, Imai K, Nakachi K, Fujiki H (2001) A new function of green tea: prevention of lifestyle-related diseases. Ann N Y Acad Sci 928:274–280PubMedCrossRef

Suganuma M, Fujiki H, Suguri H, Yoshizawa S, Hirota M, Nakayasu M, Ojika M, Wakamatsu K, Yamada K, Sugimura T (1988) Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. Proc Natl Acad Sci USA 85:1768–1771PubMedCrossRef

Suganuma M, Okabe S, Oniyama M, Tada Y, Ito H, Fujiki H (1998) Wide distribution of [³H](−)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis 19:1771–1776PubMedCrossRef

Suganuma M, Okabe S, Kai Y, Sueoka N, Sueoka E, Fujiki H (1999a) Synergistic effects of (−)-epigallocatechin gallate with (−)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res 59:44–47PubMed

Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H (1999b) Essential role of tumor necrosis factor α (TNF-α) in tumor promotion as revealed by TNF-α-deficient mice. Cancer Res 59:4516–4518PubMed

Suganuma M, Ohkura Y, Okabe S, Fujiki H (2001) Combination cancer chemoprevention with green tea extract and sulindac shown in intestinal tumor formation in Min mice. J Cancer Res Clin Oncol 127:69–72PubMedCrossRef

Suganuma M, Okabe S, Kurusu M, Iida N, Ohshima S, Saeki Y, Kishimoto T, Fujiki H (2002) Discrete roles of cytokines, TNF-α, IL-1, IL-6 in tumor promotion and cell transformation. Int J Oncol 20:131–136PubMed

Suganuma M, Kurusu M, Suzuki K, Tasaki E, Fujiki H (2006) Green tea polyphenol stimulates cancer preventive effects of celecoxib in human lung cancer cells by upregulation of GADD153 gene. Int J Cancer 119:33–40PubMedCrossRef

Suganuma M, Saha A, Fujiki H (2011) New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci 102:317–323PubMedCrossRef

Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H, Shimokawa R (1992) Effect of (−)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 65:51–54PubMedCrossRef

Tsao AS, Liu D, Martin J, Tang X-m, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V (2009) Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Rev Res 2:931–941

Tsubono Y, Nishino Y, Komatsu S, Hsieh C–C, Kanemura S, Tsuji I, Nakatsuka H, Fukao A, Satoh H, Hisamichi S (2001) Green tea and the risk of gastric cancer in Japan. N Engl J Med 344:632–636PubMedCrossRef

Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smith AMM, Bos JL (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532PubMedCrossRef

Wang ZY, Hong JY, Huang MT, Reuhl K, Conney AH, Yang CS (1992) Inhibition of N-nitrosodiethylamine- and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced tumorigenesis in A/J mice by green tea and black tea. Cancer Res 52:1943–1947PubMed

Yamane T, Hagiwara N, Tateishi M, Akachi S, Kim M, Okuzumi J, Kitao Y, Inagake M, Kuwata K, Takahashi T (1991) Inhibition of azoxymethane-induced colon carcinogenesis in rat by green tea polyphenol fraction. Jpn J Cancer Res 82:1336–1339PubMedCrossRef

Yamane T, Takahashi T, Kuwata K, Oya K, Inagake M, Kitao Y, Suganuma M, Fujiki H (1995) Inhibition of N-methyl-N’-nitro-N-nitrosoguanidine-induced carcinogenesis by (−)-epigallocatechin gallate in the rat glandular stomach. Cancer Res 55:2081–2084PubMed

Yang CS, Wang ZY (1993) Tea and cancer. J Natl Cancer Inst 85:1038–1049PubMedCrossRef

Yang GY, Liao J, Kim K, Yurkow EJ, Yang CS (1998) Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 19:611–616PubMedCrossRef

Yoshizawa S, Horiuchi T, Fujiki H, Yoshida T, Okuda T, Sugimura T (1987) Antitumor promoting activity of (−)-epigallocatechin gallate, the main constituent of “tannin” in green tea. Phytother Res 1:44–47CrossRef

Yoshizawa S, Horiuchi T, Suganuma M, Nishiwaki S, Yatsunami J, Okabe S, Okuda T, Muto Y, Frenkel K, Troll W, Fujiki H (1992) Penta-O-galloyl-β-d-glucose and (−)-epigallocatechin gallate. Am Chem Soc:316–325

Title: Challenging the effectiveness of green tea in primary and tertiary cancer prevention
Authors: Hirota Fujiki
Kazue Imai
Kei Nakachi
Masahito Shimizu
Hisataka Moriwaki
Masami Suganuma
Publication date: 01-08-2012
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 8/2012
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-012-1250-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Topics and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2012

Association of cytokeratin 17 expression with differentiation in oral squamous cell carcinoma

The link between genetic polymorphism of glutathione-S-transferases, GSTM1, and GSTT1 and diffuse large B-cell lymphoma in Egypt

Overexpression and ratio disruption of ΔNp63 and TAp63 isoform equilibrium in endometrial adenocarcinoma: correlation with obesity, menopause, and grade I/II tumors

Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3

A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis

EGFR L861Q mutation is a frequent feature of pulmonary mucoepidermoid carcinoma

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials